drugset / Trial / NCT02798471

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471

Phase 3 Completed 290 enrolled Daiichi Sankyo
RandomizedParallel-groupSingle-blindTreatment

Summary

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.

Timeline

Start
2017-03-27
Primary completion
2022-05-24
Completion
2022-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 15 mg Oral
Subject Edoxaban Small molecule 30 mg Oral
Subject Edoxaban Small molecule 60 mg Oral
Subject Enoxaparin sodium Other / unclassified
Subject Fondaparinux Other / unclassified
Subject Heparin Other / unclassified
Subject Warfarin Small molecule